Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer
Autore:
Grossi, F; Scolaro, T; Tixi, L; Loprevite, M; Ardizzoni, A;
Indirizzi:
Ist Nazl Ric Canc, Div Med Oncol, I-16132 Genoa, Italy Ist Nazl Ric Canc Genoa Italy I-16132 iv Med Oncol, I-16132 Genoa, Italy Univ Udine, Clin Oncol, I-33100 Udine, Italy Univ Udine Udine Italy I-33100 v Udine, Clin Oncol, I-33100 Udine, Italy
Titolo Testata:
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
fascicolo: 1, volume: 37, anno: 2001,
pagine: 61 - 67
SICI:
1040-8428(200101)37:1<61:TROSCI>2.0.ZU;2-Y
Fonte:
ISI
Lingua:
ENG
Soggetto:
PROPHYLACTIC CRANIAL IRRADIATION; CEREBROSPINAL-FLUID PHARMACOKINETICS; PHASE-II; COMBINATION CHEMOTHERAPY; BRONCHOGENIC CARCINOMA; COMPLETE REMISSION; NONHUMAN-PRIMATES; RADIATION-THERAPY; RANDOMIZED TRIAL; TOPOTECAN;
Keywords:
small cell lung cancer; brain metastases; systemic chemotherapy;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
44
Recensione:
Indirizzi per estratti:
Indirizzo: Ardizzoni, A Ist Nazl Ric Canc, Div Med Oncol, Largo R Benzi 10, I-16132 Genoa, Italy Ist Nazl Ric Canc Largo R Benzi 10 Genoa Italy I-16132 Italy
Citazione:
F. Grossi et al., "The role of systemic chemotherapy in the treatment of brain metastases from small-cell lung cancer", CR R ONC H, 37(1), 2001, pp. 61-67

Abstract

Brain is the most common site of metastatic spread in small-cell lung cancer (SCLC). Approximately 10%, of SCLC patients have brain metastases (BM) already at diagnosis and an additional 40% will develop central nervous system (CNS) involvement during their disease course, Although whole brain radiotherapy and corticosteroids is considered the treatment of choice. accumulating evidence suggests that systemic chemotherapy may also play an important role. The concept of the brain as a pharmacologic sanctuary site for established metastases is in contrast with recent clinical observations of frequent BM responses with systemic chemotherapy. During the last decade, several reports about the effect of systemic chemotherapy on BM from SCLC have been published. Pooled data from five studies report 66% response rate (RR)in 64 patients with initial BM. In addition, an average RR of 36% is derived from five studies including 135 patients with delayed BM treated with systemic single agent chemotherapy, Among new drugs with activity in patientswith SCLC brain metastases, camptothecin analog topotecan is one of the most promising with a 52% RR. Although whole brain radiation remains the standard treatment of established BM in SCLC there is an emerging role for systemic chemotherapy, particularly with the use of new active drugs as part ofcombined modality treatments. (C) 2001 Elsevier Science Ireland Ltd, All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/02/20 alle ore 08:19:59